Bollard Group LLC Cytom X Therapeutics, Inc. Transaction History
Bollard Group LLC
- $3.54 Billion
- Q2 2024
A detailed history of Bollard Group LLC transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Bollard Group LLC holds 712 shares of CTMX stock, worth $840. This represents 0.0% of its overall portfolio holdings.
Number of Shares
712
Previous 712
-0.0%
Holding current value
$840
Previous $2,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CTMX
# of Institutions
76Shares Held
50.2MCall Options Held
22.3KPut Options Held
22.9K-
Tang Capital Management LLC San Diego, CA7.79MShares$9.19 Million1.16% of portfolio
-
Janus Henderson Group PLC London, X06.3MShares$7.44 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$6.17 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.89MShares$5.77 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3MShares$3.54 Million0.01% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $77.8M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...